Keystone Symposia 2023: Preclinical data for SNS-101
SNS-101, a conditionally active anti-VISTA antibody, potentiates anti-tumor effects of PD-1 blockade and displays favorable pharmacokinetic and cytokine release characteristics.
Lack of selectivity has posed a significant challenge to expanding the range of immunotherapy options for patients. Checkpoints and other immunosuppressive signals are promising therapeutic targets, but widespread expression on tissues beyond the tumor microenvironment often leads to poor drug-like properties and narrow therapeutic windows that diminish efficacy and pose safety risks.
The TMAb Platform is designed to overcome this selectivity challenge by creating conditionally active antibodies that are intended to selectively activate within the low-pH tumor microenvironment.